562 related articles for article (PubMed ID: 29589315)
21. Strategy to targeting the immune resistance and novel therapy in colorectal cancer.
Gang W; Wang JJ; Guan R; Yan S; Shi F; Zhang JY; Li ZM; Gao J; Fu XL
Cancer Med; 2018 May; 7(5):1578-1603. PubMed ID: 29658188
[TBL] [Abstract][Full Text] [Related]
22. Emerging treatment options for
Ursem C; Atreya CE; Van Loon K
Gastrointest Cancer; 2018; 8():13-23. PubMed ID: 29628780
[TBL] [Abstract][Full Text] [Related]
23. Biomarkers in Colorectal Cancer: Current Research and Future Prospects.
Ogunwobi OO; Mahmood F; Akingboye A
Int J Mol Sci; 2020 Jul; 21(15):. PubMed ID: 32726923
[TBL] [Abstract][Full Text] [Related]
24. HER2 targeted therapy in colorectal Cancer: Current landscape and future directions.
Chen N; He L; Zou Q; Deng H
Biochem Pharmacol; 2024 May; 223():116101. PubMed ID: 38442793
[TBL] [Abstract][Full Text] [Related]
25. Personalized medicine and pharmacogenetic biomarkers: progress in molecular oncology testing.
Ong FS; Das K; Wang J; Vakil H; Kuo JZ; Blackwell WL; Lim SW; Goodarzi MO; Bernstein KE; Rotter JI; Grody WW
Expert Rev Mol Diagn; 2012 Jul; 12(6):593-602. PubMed ID: 22845480
[TBL] [Abstract][Full Text] [Related]
26. Translating clinical research of Molecular Biology into a personalized, multidisciplinary approach of colorectal cancer patients.
Strambu V; Garofil D; Pop F; Radu P; Bratucu M; Popa F
J Med Life; 2014 Mar; 7(1):17-26. PubMed ID: 24653752
[TBL] [Abstract][Full Text] [Related]
27. Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal Cancer.
Roviello G; D'Angelo A; Petrioli R; Roviello F; Cianchi F; Nobili S; Mini E; Lavacchi D
Transl Oncol; 2020 Sep; 13(9):100795. PubMed ID: 32470910
[TBL] [Abstract][Full Text] [Related]
28. Targeted therapeutic agents for colorectal cancer.
Chee CE; Sinicrope FA
Gastroenterol Clin North Am; 2010 Sep; 39(3):601-13. PubMed ID: 20951919
[TBL] [Abstract][Full Text] [Related]
29. Immune checkpoint inhibitors in
Kassab R; Khalil MA; Kassab J; Kourie HR
Future Oncol; 2023 Nov; 19(36):2417-2424. PubMed ID: 37990891
[TBL] [Abstract][Full Text] [Related]
30. Current and emerging biomarkers in metastatic colorectal cancer.
Lee MKC; Loree JM
Curr Oncol; 2019 Nov; 26(Suppl 1):S7-S15. PubMed ID: 31819705
[TBL] [Abstract][Full Text] [Related]
31. Molecular targeted therapy for metastatic colorectal cancer: current and evolving approaches.
Li F; Lin Y; Li R; Shen X; Xiang M; Xiong G; Zhang K; Xia T; Guo J; Miao Z; Liao Y; Zhang X; Xie L
Front Pharmacol; 2023; 14():1165666. PubMed ID: 37927605
[TBL] [Abstract][Full Text] [Related]
32. Clinical impact of tumour biology in the management of gastroesophageal cancer.
Lordick F; Janjigian YY
Nat Rev Clin Oncol; 2016 Jun; 13(6):348-60. PubMed ID: 26925958
[TBL] [Abstract][Full Text] [Related]
33. Development of a precision medicine pipeline to identify personalized treatments for colorectal cancer.
Altunel E; Roghani RS; Chen KY; Kim SY; McCall S; Ware KE; Shen X; Somarelli JA; Hsu DS
BMC Cancer; 2020 Jun; 20(1):592. PubMed ID: 32580713
[TBL] [Abstract][Full Text] [Related]
34. A review of the most promising biomarkers in colorectal cancer: one step closer to targeted therapy.
Deschoolmeester V; Baay M; Specenier P; Lardon F; Vermorken JB
Oncologist; 2010; 15(7):699-731. PubMed ID: 20584808
[TBL] [Abstract][Full Text] [Related]
35. Systematic literature review and meta-analysis of HER2 amplification, overexpression, and positivity in colorectal cancer.
Singh H; Kang A; Bloudek L; Hsu LI; Corinna Palanca-Wessels M; Stecher M; Siadak M; Ng K
JNCI Cancer Spectr; 2024 Jan; 8(1):. PubMed ID: 37815820
[TBL] [Abstract][Full Text] [Related]
36. Comprehensive genomic characterization of sporadic synchronous colorectal cancer: Implications for treatment optimization and clinical outcome.
Yang LP; Jiang TJ; He MM; Ling YH; Wang ZX; Wu HX; Zhang Z; Xu RH; Wang F; Yuan SQ; Zhao Q
Cell Rep Med; 2023 Oct; 4(10):101222. PubMed ID: 37794586
[TBL] [Abstract][Full Text] [Related]
37. Colorectal cancer genomic biomarkers in the clinical management of patients with metastatic colorectal carcinoma.
Rachiglio AM; Sacco A; Forgione L; Esposito C; Chicchinelli N; Normanno N
Explor Target Antitumor Ther; 2020; 1(1):53-70. PubMed ID: 36046264
[TBL] [Abstract][Full Text] [Related]
38. Molecular Targets for the Treatment of Metastatic Colorectal Cancer.
Cohen R; Pudlarz T; Delattre JF; Colle R; André T
Cancers (Basel); 2020 Aug; 12(9):. PubMed ID: 32825275
[TBL] [Abstract][Full Text] [Related]
39. New targeted therapies in pancreatic cancer.
Seicean A; Petrusel L; Seicean R
World J Gastroenterol; 2015 May; 21(20):6127-45. PubMed ID: 26034349
[TBL] [Abstract][Full Text] [Related]
40. A shift in focus towards precision oncology, driven by revolutionary nanodiagnostics; revealing mysterious pathways in colorectal carcinogenesis.
Sharma S; Bhattacharya S; Joshi K; Singh S
J Cancer Res Clin Oncol; 2023 Nov; 149(17):16157-16177. PubMed ID: 37650995
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
